PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. 2009 February 10; 72(6): 566–567.
PMCID: PMC2818182

Epistasis

Multiple sclerosis and the major histocompatibility complex
Sreeram V. Ramagopalan, MA and George C. Ebers, MD, FRCPC, FRCP, FMedSci

Recent studies in multiple sclerosis (MS) have taken epistasis from speculation and expectation to the reality of its key roles in susceptibility and outcome. Bateson1 first used the term epistasis to describe the effects on a biologic trait of one gene masking another. Usage has broadened to more generally encompass the explanation of phenotype. Although this has meant gene–gene interactions, environmentally mediated influences up to and including gene modification are part of this concept.2 Many prior examples of epistasis in clinical medicine may be unfamiliar but well-documented. Bhende et al.3 first demonstrated that lack of the H antigen, an intermediary point in the production of the corresponding A and B antigens at the ABO locus, prevents the expression of A and B alleles and blood is classed as O. This null phenotype, discovered among the natives of Bombay, India, was called the Bombay phenotype, to distinguish it from that of other individuals with the O blood group. At least two genes, FUT1 and FUT2, encoding alpha (1,2) fucosyltransferases, control this complex epistatic effect.

MS well illustrates informative paradigms for gene–gene interaction in complex disease. For the main association in the major histocompatibility complex (MHC) it is now clear that the notion of HLA-DRB1*15 acting solely to increase MS risk4,5 is a gross oversimplification. Three types of epistasis have been documented in the MHC4–6 where HLA-DRB1*15 haplotypes exert the single strongest effect on MS risk. These dwarf any non-MHC effect but it took large cohorts and systematic methods of analysis to make progress. Several epistatic interactions were uncovered between MHC alleles or haplotypes, fundamental in determining susceptibility to MS. These had remained occult over the three decades since the MHC association was first described because they had to be specifically sought. The key strategy was to examine families lacking HLA-DRB1*15 to control for the obligate distorted transmission of all alleles from parents secondary to this primary association.4,5 When these families were studied, it emerged that many other alleles were operative in risk. A genotype- rather than allele- or haplotype-dependent hierarchy unfolded (figure). At an individual level this can be grouped into the following three types.

figure znl0060962840001
Figure Genotypic relative risks for multiple sclerosis (MS) for combinations of alleles at the HLA-DRB1 locus

DOMINANT NEGATIVE EPISTASIS

HLA-DRB1*14, dominantly protective, has a stronger effect in reducing than HLA-DRB1*15 has in increasing susceptibility. This allele abrogates risk associated with HLA-DRB1*15, so that a HLA-DRB1*14/*15 genotype has a risk of 1 (compared to a HLA-DRB1*15 allelic risk of 3)4 (figure). As yet, no functional explanation can be given for the dominant protective effect of HLA-DRB1*14, which extends to other susceptible haplotypes. Understanding this epistatic interaction could be critical for treatment or prevention.

SYNERGISTIC EPISTASIS

On its own, HLA-DRB1*08 modestly increases the risk of MS but when present in conjunction with HLA-DRB1*15 on the other parental haplotype, it more than doubles the risk associated with a single copy of HLA-DRB1*154 (figure). This observation highlights how a variant with a marginal independent effect on risk may turn out to have a strong effect in certain genetic backgrounds. Indeed, using case–control analyses, an association may only be observed when allele frequencies are statistically different. However, if an effect of a gene on disease depends on the presence/absence of other genes, variations across populations in allele frequencies among interacting loci can markedly affect the power to detect effects.7 This phenomenon may result in false negative association results.7

EPISTASIS AND CLINICAL PHENOTYPE

Modifier genes represent biologic phenomena that few clinicians can ignore in the genomic era. HLA-DRB1*01 and HLA-DRB1*15 alleles interact to influence MS clinical phenotypes, producing a milder disease course,6 but play very little or no role in modifying clinical course independently. These interacting genetic variants clearly affect critically important long term phenotypes, holding potential for developing potential therapeutic strategies. HLA-DRB5*0101 interacts with HLA-DRB1*15 to reduce the number of autoreactive CD4+ T cells in experimental autoimmune encephalomyelitis, reducing its severity.8 HLA-DRB1*01 may operate in a similar manner. Furthermore, HLA-DRB1*01 may operate differently in disease susceptibility as compared to clinical outcome.

Recent genome-wide association studies9 have received wide attention and more associations may come from small genetic isolates. However, effects confirmed to date with this methodology (explaining perhaps 1% of risk variance) are more than an order of magnitude smaller than these recently described epistatic effects evident within the MHC. The net effect of the two parental haplotypes in combination can be conveniently called the diplotype.

Although the genetic architecture of the MHC is unlike that of any other region of the genome, and epistasis is likely to have arisen as an evolutionary advantage, the lessons learnt from the MS HLA association are unlikely to be unique. Common episodic neurologic disorders such as migraine and epilepsy seem good candidates for disease- associated gene-masking by epistatic loci.10 Ion channel variation leading to greater than average inhibitory/excitatory influences may be masked by protective polymorphisms reducing clinical penetrance and expressivity.

Epistasis is no longer a textbook anomaly illustrated by remote animal models. Recent studies show it to be at the heart what is most clinically relevant in MS—susceptibility and disability outcome.

Notes

Address correspondence and reprint requests to Professor George C. Ebers, University Department of Clinical Neurology, Level 3, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK ku.ca.xo.oruenlc@srebe.egroeg

Disclosure: The authors report no disclosures.

Received August 12, 2008. Accepted in final form October 31, 2008.

REFERENCES

1. Bateson W. Mendel’s Principles of Heredity. Cambridge: Cambridge University Press; 1909.
2. Waddington CH. The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin; 1957.
3. Bhende YM, Deshpande CK, Bhatia HM, et al. A “new” blood group character related to the ABO system. Lancet 1952;1:903–904. [PubMed]
4. Ramagopalan SV, Morris AP, Dyment DA, et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 2007;3:e150. [PubMed]
5. Dyment DA, Herrera BM, Cader MZ, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005;14:2019–2026. [PubMed]
6. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007;104:20896–20901. [PubMed]
7. Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 2005;37:413–417. [PubMed]
8. Gregersen JW, Kranc KR, Ke X, et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006;443:574–577. [PubMed]
9. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851–862. [PubMed]
10. Glasscock E, Qian J, Yoo JW, Noebels JL. Masking epilepsy by combining two epilepsy genes. Nat Neurosci 2007;10:1554–1558. [PubMed]

Articles from Neurology are provided here courtesy of American Academy of Neurology